{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urologic+Diseases&page=9", "query": { "condition": "Urologic Diseases", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 7007, "total_pages": 701, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urologic+Diseases&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urologic+Diseases&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T18:01:20.454Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00853242", "title": "Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Failure, Chronic" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Genz-644470", "type": "DRUG" }, { "name": "Sevelamer carbonate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 349, "start_date": "2009-02", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2015-05-01", "last_synced_at": "2026-10-14T18:01:20.454Z", "location_count": 52, "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Hot Springs, Arkansas + 49 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00853242" }, { "nct_id": "NCT00805779", "title": "Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Urinary Bladder, Overactive" ], "interventions": [ { "name": "MagPro R30", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "EMKinetics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2008-12", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2011-06-08", "last_synced_at": "2026-10-14T18:01:20.454Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00805779" }, { "nct_id": "NCT01788046", "title": "Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hyperparathyroidism, Secondary" ], "interventions": [ { "name": "Etelcalcetide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 515, "start_date": "2013-03-12", "completion_date": "2014-05-09", "has_results": true, "last_update_posted_date": "2019-08-20", "last_synced_at": "2026-10-14T18:01:20.454Z", "location_count": 45, "location_summary": "Mobile, Alabama • Azusa, California • Beverly Hills, California + 42 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Azusa", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Fairfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01788046" }, { "nct_id": "NCT01367886", "title": "Comparative Urine Proteomic Studies of Overactive Bladder in Humans", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Overactive Bladder" ], "interventions": [ { "name": "fesoterodine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 21, "start_date": "2010-08", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2015-02-27", "last_synced_at": "2026-10-14T18:01:20.454Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01367886" }, { "nct_id": "NCT07146854", "title": "EndoForce Post Approval Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "End Stage Renal Disease (ESRD)" ], "interventions": [], "intervention_types": [], "sponsor": "Phraxis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2026-01-13", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-10-14T18:01:20.454Z", "location_count": 2, "location_summary": "Orangeburg, South Carolina • Spartanburg, South Carolina", "locations": [ { "city": "Orangeburg", "state": "South Carolina" }, { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07146854" }, { "nct_id": "NCT01853046", "title": "Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Regorafenib (Stivarga, BAY73-4506)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2013-06", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-02-20", "last_synced_at": "2026-10-14T18:01:20.454Z", "location_count": 5, "location_summary": "Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01853046" }, { "nct_id": "NCT05099770", "title": "Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus", "Chronic Kidney Diseases" ], "interventions": [ { "name": "Renal Autologous Cell Therapy (REACT/ rilparencel)", "type": "BIOLOGICAL" }, { "name": "Sham Comparator", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Prokidney", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "30 Years to 80 Years" }, "enrollment_count": 685, "start_date": "2022-01-05", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-14T18:01:20.454Z", "location_count": 75, "location_summary": "Huntsville, Alabama • Tucson, Arizona • Beverly Hills, California + 59 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Granada Hills", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05099770" }, { "nct_id": "NCT04599283", "title": "BE Technologies Mobile Uroflowmetry Validation Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "BPH", "BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms", "BPH Without Urinary Obstruction", "BPH Without Urinary Obstruction With Other Lower Urinary Tract Symptoms", "Lower Urinary Tract Symptoms", "Overactive Bladder", "Overactive Bladder Syndrome", "Urinary Obstruction", "Urinary Incontinence, Urge" ], "interventions": [ { "name": "MenHealth Uroflowmeter", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "BE Technologies Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "MALE", "summary": "18 Years to 90 Years · Male only" }, "enrollment_count": 54, "start_date": "2020-08-18", "completion_date": "2021-02-25", "has_results": false, "last_update_posted_date": "2021-03-03", "last_synced_at": "2026-10-14T18:01:20.454Z", "location_count": 1, "location_summary": "Virginia Beach, Virginia", "locations": [ { "city": "Virginia Beach", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04599283" }, { "nct_id": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive", "Adenocarcinoma", "Bile Duct Cancer", "Biliary Tract Cancer", "Bladder Cancer", "Breast Cancer", "Breast Neoplasm", "Carcinoma, Ductal", "Carcinoma, Hepatocellular", "Cancer", "Lung Cancer, Non-Small-Cell", "Carcinoma, Ovarian Epithelial", "Carcinoma, Small Cell", "Carcinoma, Squamous", "Carcinoma, Transitional Cell", "Colorectal Cancer", "Esophagogastric Junction Neoplasms", "Inflammatory Breast Cancer", "Stomach Neoplasms", "Malignant Neoplasms", "Ovarian Neoplasms", "Pancreatic Cancer", "HER2-positive Solid Tumors", "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER-2 Protein Overexpression", "HER-2 Gene Amplification", "Prostate Cancer", "Head and Neck Cancer", "Endometrial Cancer", "Lung Cancer, Small Cell" ], "interventions": [ { "name": "CT-0508", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Carisma Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-02-02", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2024-12-18", "last_synced_at": "2026-10-14T18:01:20.454Z", "location_count": 7, "location_summary": "Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04660929" }, { "nct_id": "NCT02223429", "title": "Neurobiological Bases of Paternal Nurturance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Oxytocin", "type": "DRUG" }, { "name": "Vasopressin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James K. Rilling, PhD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2014-08", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2017-06-05", "last_synced_at": "2026-10-14T18:01:20.454Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02223429" } ] }